Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
CJC-1295 is a growth hormone secretagogue, a class of peptides designed to signal the body to produce its own growth hormone, offering a safer and more physiological approach to body composition than synthetic alternatives
FOXO4-DRI vs nearby senolytics Option FOXO4-DRI Type D-retro-inverso peptide Human trial stage None (preclinical only) Option Dasatinib + Quercetin (D+Q) Type Small-molecule drug + flavonoid Human trial stage Early human trials (e.g., Alzheimer's) Option Navitoclax Type BCL-2 family inhibitor Human trial stage Later-stage trials (e.g., myelofibrosis) D+Q and navitoclax are further along in humans but can affect healthy cells (e.g., low platelets)
Important: Ubiquinol is a food supplement, not a medicine
Last year, a study revealed people with diabetes who use the drugs could face double the risk of developing age-related macular degeneration, while reports based on adverse event reporting systems and matched cohort studies have suggested some GLP-1 medications have the potential to cause an eye disorder called non-arteritic anterior ischaemic optic neuropathy
